Adaptimmune Therapeutics Plc Total Liabilities

Adaptimmune Therapeutics Plc (ADAP) currently reports a total liabilities of $200M as of June 2025. That compares with $230M in the prior-year period — down 10.6% year over year. Use the charts on this page to explore Adaptimmune Therapeutics Plc's total liabilities history and peer comparisons.

Adaptimmune Therapeutics Plc's total liabilities decreased from $230M to $200M — a 10.6% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adaptimmune Therapeutics Plc reported $200M in total liabilities as of June 2025. That compares with $230M in the prior-year period — down 10.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $200M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adaptimmune Therapeutics Plc, and consider following ADAP for alerts when major investors trade the stock.

Adaptimmune Therapeutics Plc is classified in the Healthcare sector. On total liabilities, it currently shows $200M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADAP with unrelated industries.